Niklas Klümper: ASCO abstracts on phase EV-202 results have just been released
Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the University Hospital Bonn, shared on X:
“Very exciting! ASCO abstracts on phase EV-202 results have just been released:
Anti-NECTIN4 Enfortumab vedotin with disappointing efficacy in biomarker-unselected population beyond urothelial carcinoma.
Confirmed ORR in
– esophageal cancer 18.2%
– gastric cancer 9.5%
– NSCLC: Non-squamous 14.0%, squamous 8.3%
– Breast: TNBC 19.0%, HR+/HER2- 15.6%
Substantially lower compared to single-agent EV efficacy in metastatic urothelial carcinoma is 40-45%!
Allcomer setting for EV seems not to work beyond UC!
We need biomarkers to tailor EV treatment! Pre-selection based on NECTIN4 expression could be relevant!”
Source: Niklas Klümper/X